NCT00749567 - Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions

Non-small-cell Lung Cancer

Interventions

DRUG

Erlotinib

Erlotinib 150mg daily, continuously, until disease progression or the appearance of unacceptable toxicity

DRUG

Bevacizumab

Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression or the appearance of unacceptable toxicity

Trial Locations (10)

University Hospital of Heraklion, Heraklion

University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupoli

"Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine", Athens

401 Military Hospital, Medical Oncology Unit, Athens

Air Forces Military Hospital, Dep of Medical Oncology, Athens

"IASO General Hospital of Athens, 1st Dep of Medical Oncology", Athens

Sismanogleio General Hospital, 1st, 2nd Dep of Pulmonary Diseases, Athens

"Sotiria General Hospital, 1st, 3rd, 8th Dep of Pulmonary Diseases", Athens

"Metaxa's Anticancer Hospital of Piraeus,1st Dep of Medical Oncology", Piraeus

"Theagenion Anticancer Hospital of Thessaloniki", Thessaloniki